Immune Checkpoint Inhibitors May Trigger Severe Type 1 Diabetes After Surgery

Immune checkpoint inhibitors have transformed cancer treatment by helping the immune system recognize and attack cancer cells. However, this same immune activation can sometimes backfire, triggering the immune system to attack the body's own tissues—a category of side effects called immune-related adverse events.

A case series published in the Journal of Medical Case Reports documents three patients with advanced gastric cancer who developed fulminant Type 1 diabetes after undergoing surgery while being treated with nivolumab, an immune checkpoint inhibitor, combined with chemotherapy. Fulminant Type 1 diabetes is a rare, rapidly progressing form of the disease that develops over days or weeks rather than the months or years typical of autoimmune Type 1 diabetes.

The first patient, a 46-year-old woman, developed diabetic ketoacidosis and Type 1 diabetes 37 days after surgery. The second, a 78-year-old man, developed Type 1 diabetes and another autoimmune skin condition called bullous pemphigoid just 13 days after his procedure. The third, a 64-year-old man, developed suspected immune-related inflammation of the brain only 2 days after surgery.

All three patients had received nivolumab therapy combined with chemotherapy (S-1 and oxaliplatin) before their surgical procedures. All required intensive care unit admission, with some needing temporary ventilatory support to manage their severe immune-related complications.

While immune checkpoint inhibitors have proven effective against certain cancers, immune-related adverse events remain under-recognized in the perioperative period—the time surrounding surgery. These cases demonstrate that severe complications like fulminant Type 1 diabetes can emerge suddenly in cancer patients on this therapy.

The development of Type 1 diabetes triggered by immune therapy represents the immune system's shift from attacking cancer cells to attacking insulin-producing cells in the pancreas. This distinction is important: this is an immune-related side effect of cancer treatment, not a separate disease diagnosis unrelated to therapy.

Patients undergoing cancer surgery while on immune checkpoint inhibitor therapy should be monitored closely for signs of rapid-onset diabetes, including unusual thirst, frequent urination, unexplained fatigue, or rapid breathing. These symptoms warrant immediate medical evaluation.

Healthcare providers caring for cancer patients on nivolumab or similar agents need to maintain awareness that immune-related adverse events can emerge during or shortly after surgery. Early recognition of fulminant Type 1 diabetes and other immune complications is critical, as these conditions may require intensive care management and can be life-threatening if untreated.

Source: Journal of medical case reports. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.